---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349198"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2026-08-13T20:11:18+00:00"
generated_at: "2026-08-13T20:13:16.626288+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio Q2 net loss narrows to $3.9M; cash $320M, pipeline advances

## Summary
- Q2 2026 net loss $3.9M ($0.20/share) vs $10.2M ($1.33) in Q2 2025; revenue from Gilead $13.4M incl. $5.1M catch-up.
- Cash $320.4M at June 30, up from $226.6M; $115M gross financing completed; runway into 2029 incl. $75M Gilead fee due Q4 2026.
- ABI-6250 expanded into cholestatic liver diseases (PBC, PSC); Phase 2 study expected Q1 2027.
- GS-1179 selected for HSV HPI program; Phase 2 initiation expected by year-end 2026; opt-in decision on 40% U.S. cost-profit share by year-end.

## SEC filing metadata
- accession: 0001193125-26-349198
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2026-08-13T20:11:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312526349198/0001193125-26-349198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312526349198/asmb-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349198
- JSON: https://secwatch.observer/filing/0001193125-26-349198.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349198.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.